Clinical trial
Open access
Oct 2026
A multi-center, single-arm, phase 2 trial of dasatinib in T follicular helper cell lymphomas
T follicular helper cell lymphomas (TFHL) harbor activating T cell receptor (TCR) signaling mutations and epigenetic alterations, such as TET2 mutations. Here, we conduct a multi-center, single-arm, phase 2 trial of the tyrosine kinase inhibitor dasatinib in patients with relapsed/refractory TFHLs (jRCT2031190079). The...
S. Suma, M. Sakata-Yanagimoto, Y. Suehara et al.
· Nature Communications · 0 citations